This protocol addresses patients with medication-induced hyperprolactinemia who have developed long-term hypogonadism — presenting as hypogonadal symptoms or low bone mass — in cases where the causative drug cannot be discontinued or substituted with an alternative.
The defining challenge is an irreplaceable medication driving elevated prolactin and sustained gonadal suppression. When hypogonadal symptoms or low bone mass are present and the drug cannot be changed, a dedicated treatment strategy for the resulting hypogonadism is required.
The structured approach involves sex hormone replacement therapy. The specific agent, dosing parameters, and individualized decision pathway are detailed in the full protocol.